华盛顿特区—使用 Absorb 生物可吸收血管支架（BVS; Abbott Vascular）似乎是治疗支架内再狭窄的一个安全和有效的选择，但一项小型研究的急性和晚期血管造影结果表明，“可消失”支架的性能不如 Xience everolimus 洗脱金属支架（雅培血管）。 上周在华盛顿特区举行 ...

Abbott, the global healthcare company, on Thursday announced the launch of XIENCE Sierra Everolimus (drug) Eluting Coronary Stent System in India. According to the company, XIENCE Sierra is one of ...

EES, everolimus-eluting stent; MI, myocardial infarction; PES, paclitaxel-eluting stent; TLR, target lesion revascularization ZES, zotarolimus-eluting stent. Schematic of the three-component ...

EES versus PES effectiveness data based on Stone et al, 2008. EES versus PES safety data based on Stone et al, 2009. ZES versus PES effectiveness data based on Leon et al, Transcatheter ...

Abbott Laboratories new drug-coated heart stent, Xience V, seems to outperform market leader Taxus 2 and so could win federal approval in US. There was no difference between Xience and Taxus in ...

The drug-eluting coronary stent system improves upon previous versions of XIENCE with an enhanced stent design, a new delivery system, and unique sizes to help doctors treat challenging cases.